Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › ELTX

Elicio Therapeutics

ELTX Lead: Phase 2 ★ Read the deep dive → 8 Biotech Distilled articles ↓ 29 filings & releases ↓ Cash $30.9M (Sep 30, 2026) ↓ 8 verdicts ↓
Oncology Nucleic AcidPeptide

Market cap $42.7M 28.3M shares (10-Q, Nov 3, 2026) × $1.51 close Nov 6, 2026

Most recent annual filing: 2026-03-12

Pipeline (6 active programs)

Technology platforms

AMP · MIT

Amphiphile (AMP) technology — lymph node-targeted delivery platform using albumin hitchhiking to deliver peptides, proteins, nucleic acids and small molecules to lymph nodes; applications in cancer immunotherapy (mKRAS, BRAF, TP53 neoantigen vaccines), CAR-T and TCR-T cell therapy enhancement, prophylactic vaccines, and autoimmune disease

Targets: KRAS, BRAF, TP53

AMP

Amphiphilic lipid-modified (AMP) delivery platform that targets immunotherapy directly to lymph nodes via albumin trafficking; originally developed at MIT; enables delivery of disease-specific antigens, adjuvants, and immunomodulators to drive adaptive immunity; broad oncology focus including mKRAS-driven and BRAF-driven cancers and p53 hotspot mutations.

Targets: KRAS, BRAF, p53

Capital (as filed)

Cash
$30.9M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$10.4M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$30.9M cash, runway Q2 2027 per the update of Nov 5, 2026 — the company's own words as read there, not the filed figure

Offering documents (1)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (8)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (8 calls)

Every verdict Biotech Distilled has published on Elicio Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-06-12 Watch Elicio Therapeutics (ELTX) - Scientific Deep Dive for ELI-002 7P and the AMP Pipeline Differentiated KRAS vaccine science with imminent binary DFS readout, but zero randomized efficacy data, going-concern balance sheet, and a freshly validated pan-RAS competitor entering the same adjuvant trial make this a speculation to size as a lottery ticket, not a position to underwrite.
  2. 2026-06-15 Avoid UPDATE: Elicio Therapeutics (ELTX) - The Binary Broke AMPLIFY-7P missed its pre-specified ITT primary DFS endpoint (HR 0.85, p=0.53), the post-hoc R0 rescue subgroup is unproven and unfundable, cash runway extends only into Q4 2026, and the GKCC secured note holder sits ahead of common equity.
  3. 2026-06-17 Watch UPDATE: Elicio Therapeutics (ELTX) - Three Complete Responses and a Lifeline Narrative A 3/3 complete response signal in MSS metastatic PDAC against a 0–8% historical CR rate opens a coherent second path through metastatic combination, but n=3 is n=3, the balance sheet is unchanged, and re-engagement requires a credible partnership or non-dilutive financing.
  4. 2026-06-24 Watch UPDATE: Elicio Therapeutics (ELTX) - The KOLs Showed Up, the Checkbook Didn't KOLs validated the 3/3 CR signal against a 0–8% historical bar and the Phase 1 design crystallized, but no partner stepped up and the funding gate remains the binding constraint.
  5. 2026-07-02 Avoid UPDATE: Elicio Therapeutics (ELTX) - The Financing Tell Landed A $15M registered direct at a 12% discount with no strategic partner — the disqualifying dilutive outcome flagged as the downside marker — confirms the funding path is generalist and dilutive, not strategic, with another raise already visible on the horizon.
  6. 2026-08-11 Avoid UPDATE: Elicio Therapeutics (ELTX) - Somebody Else Is Paying Lustgarten/Break Through Cancer funding an MSK neoadjuvant Phase 1 is genuine third-party scientific validation and free clinical optionality, but it is not a named partner or non-dilutive capital to Elicio, and the structural balance-sheet problem is unchanged.
  7. 2026-10-24 Avoid UPDATE: Elicio Therapeutics (ELTX) - The Rescue Narrative Gets a Rewrite The ctDNA-adjusted analysis (HR 0.47, p=0.0086) and Nature Medicine publication make the June miss look more like randomization bad luck, but the primary endpoint still failed, subgroup p-values are nominal, cash guidance has reached the current quarter, and no partner or non-dilutive Phase 3 funding has materialized.
  8. 2026-11-06 Avoid UPDATE: Elicio Therapeutics (ELTX) - The Apex Predator Becomes the Combo Partner Runway extended to Q2 2027 via ATM dilution and a daraxonrasib combo Phase 1 is targeted for Q4 2026, but no RevMed agreement is disclosed, Q3 ATM issuance averaged ~$2/share, GKCC principal payments start the quarter after runway ends, and the Phase 3 remains unfunded.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (29)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 10, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

6 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)